In deciding whether a substance can be added to the 503A bulk compound list, the FDA assesses its physical and chemical characterization, safety issues, available evidence of effectiveness, and how it has historically been used in compounded products
Ursini F, Heim S, Kiess M, Maiorino M, Roveri A, Wissing J, Floh L
This section delineates SFNs multifaceted mechanisms across epigenetic regulation, programmed cell death pathways (particularly ferroptosis), and tumor immune microenvironment remodeling, establishing its role as a truly multi-targeted therapeutic agent
It is especially important for the regular operation of dysfunctional mitochondria, helping to remove toxins and playing a vital role in energy production and expenditure in cells